Atlas Trials

Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment

Clinical trial NCT04363216 · UNKNOWN

Trial details

NCT number
NCT04363216
Sponsor
Thomas Jefferson University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2020-05-01
Primary completion
2021-05-01
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.